reduced the risk of major adverse cardiovascular events when added to low-dose aspirin in stable patients with prior myocardial infarction, resulting in the approval of ticagrelor 60 mg twice daily for long-term secondary prevention. We investigated the incidence of stroke, outcomes after stroke, and the efficacy of ticagrelor focusing on the approved 60 mg twice daily dose for reducing stroke in this population.
s troke remains one of the most feared adverse cardiovascular events because it is a leading cause of long-term disability and remains within the top 5 causes of death in the United States. 1 Each year ≈800 000 people in the United States experience a stroke with ischemic stroke being the most common type (87%). It is estimated that in 2010, 11.6 million incident ischemic strokes occurred globally. 1 Although patients who have experienced a stroke are at heightened risk of recurrence, the majority of strokes (≈80%) are first events rather than recurrent events. 1 To reduce stroke rates, vulnerable populations must therefore be identified for preventive interventions. Patients with uncontrolled hypertension and atrial fibrillation are clearly at heightened risk. Among the remaining vulnerable groups, patients with symptomatic atherosclerosis in any territory, including prior myocardial infarction (MI), are at heightened risk of atherothrombotic stroke. 2, 3 Whereas the benefits of more intensive antiplatelet strategies in patients with prior MI would be expected to be reduced and indeed are driven by reductions in recurrent coronary events, the observation of an additional benefit in reducing stroke may have important implications for patients and clinicians weighing the overall risks and benefits of therapy.
The PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54) was designed to test prospectively the hypothesis that the addition of ticagrelor to aspirin would reduce cardiovascular risk in patients with prior MI. Overall, both ticagrelor 60 mg twice daily and ticagrelor 90 mg twice daily reduced the composite of cardiovascular death, MI, or stroke by ≈15% over long-term follow-up. Although both doses were efficacious, the 60-mg dose was to be better tolerated, leading to the approval of this dose as long-term secondary prevention.
In this analysis, we investigate the incidence, predictors, and subsequent outcomes of stroke. We also evaluate the effect of the approved ticagrelor 60-mg dose added to aspirin on the risk of stroke, specifically both ischemic and hemorrhagic stroke. Last, we examine whether the effects of ticagrelor 60 mg in PEGASUS-TIMI 54 were consistent with observations from other trials evaluating more intensive antiplatelet therapy in long-term trials of secondary prevention in patients with coronary disease.
MethODs study Population
PEGASUS-TIMI 54 randomly assigned patients with prior MI to ticagrelor 60 mg twice daily, ticagrelor 90 mg twice daily, or placebo, all on a background of low-dose aspirin. The protocol was approved by the relevant ethics committee at each participating site. Written informed consent was obtained from all the patients. The design 4 and primary results of the trial have been published. 5 A total of 21 162 patients were enrolled, with 14 112 allocated to either placebo or ticagrelor 60 mg twice daily. Patients aged at least 50 years were enrolled with a spontaneous MI occurring 1 to 3 years before enrollment and at least one of the following additional high-risk features: age of ≥65 years, diabetes mellitus requiring medication, a second prior spontaneous MI, multivessel coronary artery disease, or chronic renal dysfunction, defined as a creatinine clearance <60 mL/min as estimated by the Cockroft-Gault equation. Patients were ineligible if there was planned use of a P2Y 12 receptor antagonist or anticoagulant therapy during the study period; if they had a bleeding disorder, a history of intracranial bleeding, a central nervous system tumor, or an intracranial vascular abnormality; or if they had had gastrointestinal bleeding within the previous 6 months or major surgery within the previous month. Early in the course of the trial, observations of bleeding risks in other trials of different antiplatelet therapies in patients with known prior stroke resulted in an amendment to the protocol excluding these patients from PEGASUS-TIMI 54. 4 Therefore, few patients with prior stroke were enrolled, and those that were randomized were discontinued from therapy early in the course of the trial.
end Points
The primary efficacy end point for PEGASUS-TIMI 54 was the composite of cardiovascular death, MI, or stroke, and the clinical Perspective What is new?
• Intensive antiplatelet therapy as long-term secondary prevention in patients with prior myocardial infarction is anticipated to reduce the risk of coronary events. • This study demonstrates that long-term ticagrelor reduced stroke through a reduction in ischemic stroke and did not increase hemorrhagic stroke. • When pooled with other studies investigating potent antiplatelet therapy for long-term secondary prevention after myocardial infarction, results show a consistent reduction in ischemic stroke.
What are the clinical implications?
• When considering intensive antiplatelet regimens for long-term secondary prevention, clinicians and patients must weigh benefits and risks. • Although these therapies are anticipated to reduce both de novo and stent-related coronary events, this analysis highlights broader benefits in reducing ischemic stroke. These data may be useful in clinical decision making. • Overall, for 1000 patients initiated on ticagrelor 60 mg twice daily for 3 years, 13 primary end-point events would be prevented, including ≈5 ischemic strokes. This benefit would come at a cost of 9 TIMI major bleeds but no hemorrhagic strokes or fatal bleeds.
ORIGINAL RESEARCH ARTICLE 863 primary safety end point was TIMI major bleeding. For the current analysis, stroke was the primary efficacy outcome. Stroke was a prespecified component of the overall trial primary end point. A stroke end point was defined as the new onset of focal neurological symptoms lasting >24 hours or evidence of new infarct on brain imaging even if symptoms were <24 hours in duration. 4 Stroke events were further classified as ischemic or primary hemorrhagic. Ischemic strokes that were associated with hemorrhagic conversion were also identified. Nonhemorrhagic infarction with hemorrhagic conversion was defined as evidence of cerebral infarction with blood thought to represent hemorrhagic conversion and not a primary hemorrhage based on location and imaging characteristics. All potential stroke events were adjudicated by a clinical events committee composed of specialists in neurology who were blinded to treatment allocation. 4 Site investigators were trained in the assessment of disability after stroke by using the modified Rankin scale (mRS). Investigators were instructed to complete an assessment at 30 days after discharge. Scores on the mRS increase with greater disability and range from 0 (no symptoms at all) to a maximum of 6 (death) with a score of 3 indicating moderate disability. 7
statistical considerations
Baseline characteristics were summarized using either medians and quartiles for continuous variables or frequencies and percentages for categorical variables. Differences were tested with the Wilcoxon rank-sum test for continuous variables and with the Pearson χ 2 test for categorical data. Cumulative event rates at 3 years were calculated by the Kaplan-Meier method. Hazard ratios (HRs) and 95% confidence intervals (CIs) were generated with the use of a Cox proportional-hazards model, and all reported P values are 2-sided. Efficacy analyses were performed on an intention-to-treat basis. Safety analyses included all the patients who received at least 1 dose of study drug and included all the events occurring after receipt of the first dose and within 7 days of the last dose of study drug. The primary analysis focused on the efficacy and safety of the ticagrelor 60-mg dose that is approved for long-term use. Results for the 90-mg ticagrelor dose are presented in the online-only Data Supplement. Subgroup analyses were done to evaluate the consistency of effects. A 2-sided P value of <0.05 was considered significant. Analyses were performed using SAS version 9.4 (SAS Institute Inc.).
To put these data in the context of the totality of evidence, data from other large, long-term placebo-controlled trials of more intensive antiplatelet therapy in patients with coronary artery disease were combined into a meta-analysis. [8] [9] [10] [11] Detailed methodology is presented in the online-only Data Supplement. Trials meeting the criteria were combined by using a randomeffects model with weighting based on the inverse variance (Comprehensive Meta-Analysis version 3.3.070, Biostat Inc).
resUlts

Baseline characteristics
Of the 14 112 patients randomly assigned to either placebo or ticagrelor 60 mg twice daily, a total of 213 patients experienced a stroke during a median of 33 months of follow-up. The majority of first strokes were ischemic (181, 85%). Of these 181 strokes, 173 subjects had ischemic stroke event, and a subset of 8 patients had an ischemic stroke with hemorrhagic conversion in addition. The other types of strokes include 16 strokes hemorrhagic (16, 8%) , and unknown (16, 8%, online-only Data Supplement Figure I ). The baseline characteristics of patients who did and did not experience a stroke during follow-up are shown in Table 1 . Patients who experienced a stroke were older, had higher systolic blood pressure at randomization, and more frequently had comorbidities including a history of hypertension, diabetes mellitus, and impaired renal function. Patients with stroke were more likely to have more extensive cardiovascular disease, including a history of congestive heart failure, and a history of atrial fibrillation. Because of the early modification of the protocol excluding these patients, the number of patients with a history of stroke was small (n=62, <1% of the analysis cohort).
Outcomes after stroke
Of those patients that experienced a stroke, 180 (85%) were hospitalized for a median duration of 8 days (interquartile range, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . A total of 87% of patients with strokes had residual disability at or beyond 24 hours, whereas 13% were asymptomatic at 24 hours but had brain-imaging data documenting a stroke. Of patients hospitalized for a stroke, 26 (14%) died in hospital. Of the patients who were discharged alive, 19 (12%) were unable to return home and required a higher level of care at either a nursing home or another acute care facility. At 6 months after discharge, another 14 (9%) of the patients that survived the index hospitalization for stroke had died. Sites were asked to collect a mRS at 30 days from the stroke event. In addition to the 18% (39/213) of strokes that were fatal, another 15% (33/213) led to either moderate or severe disability (mRS, 3-5).
reduction of stroke With ticagrelor
Stroke of any kind was significantly reduced with ticagrelor 60 mg twice daily relative to placebo (HR, 0.75; 95% CI, 0.57-0.98; P=0.034; Table 2 , Figure 1 ). This reduction in stroke was driven by a reduction in ischemic stroke (HR, 0.76; 95% CI, 0.56-1.02; Table 2 ). Hemorrhagic stroke was infrequent overall and not statistically different between treatment groups (placebo=9, ticagrelor 60 mg=8; Table 3 ) as was ischemic stroke with hemorrhagic conversion (placebo=5, ticagrelor 60 mg=4; Table 3 ). The reduction in stroke with ticagrelor 60 mg versus placebo appeared largely consistent across relevant subgroups at heightened risk of stroke based on demographics and comorbidities (online-only Data Supplement Table I ). Data for the efficacy and safety of the ticagrelor 90 mg twice daily dose were generally similar (online-only Data Supplement Tables I and II) .
The efficacy of ticagrelor in reducing strokes that resulted in at least moderate disability or death (mRS, 3-6; HR, 0.57; 95% CI, 0.33-0.99; P=0.045) seemed, if anything, even greater than its effect on less severe strokes resulting in no or minimal disability (mRS, 0-2; HR, 0.81; 95%, CI 0.56-1.17; P=0.26; Figure 2 , online-only Data Supplement Figure II) .
Overall safety and efficacy of ticagrelor
Ticagrelor 60 mg twice daily increased TIMI major bleeding (HR, 2.32; 95% CI, 1.68-3.21; P<0.001) but with no statistically significant increase in intracranial hemorrhage (HR, 1.33; 95% CI, 0.77-2.31; P=0.31) or fatal bleeding (HR, 1.00; 95% CI, 0.44-2.27; P=1.00; Tables 4 and  5 ). Ticagrelor 60 mg twice daily reduced the composite of cardiovascular death, MI, or stroke (HR, 0.84; 95% CI, 0.74-0.95; P=0.0043) and did not result in any excess of all-cause mortality (HR, 0.89; 9% CI, 0.76-1.04; P=0.14; Table 4 ). Considering absolute risk, for 1000 patients initiated on ticagrelor 60 mg twice daily for 3 years, 13 primary end-point events would be prevented including ≈5 ischemic strokes. This benefit would come at a cost of 9 TIMI major bleeds but no hemorrhagic strokes or fatal bleeds. 
Meta-analysis of reduction of stroke With More intensive antiplatelet strategies
Combining data from a total of 4 randomized, long-term placebo-controlled trials of more versus less intensive antiplatelet therapy in 44 816 patients with coronary disease who experienced a total of 532 strokes (online-only Data Supplement Table III ) demonstrated a significant 28% reduction in stroke in patients treated with more intensive therapy (HR, 0.72; 95% CI, 0.60-0.85; P<0.001, Figure 3A ) with no evidence of heterogeneity (P value for heterogeneity, 0.76; I 2 , 0%). As expected, the effects of more intensive antiplatelet therapy on ischemic stroke ( Figure 3B ) were more pronounced with a 34% reduction (HR, 0.66; 95% CI, 0.54-0.81; P=0.0001). There was no significant effect on hemorrhagic stroke (HR, 1.29; P=0.48; Figure 3C ), but with broad 95% CIs (0.64-2.59) because of the smaller number of events. There was some evidence for moderate heterogeneity (I 2 , 29%). When the data from TRA2P-TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic
Events [TRA 2P]-Thrombolysis in Myocardial Infarction
[TIMI] 50 trial) were limited to patients only on background aspirin monotherapy (ie, excluding patients on background aspirin + thienopyridine, in whom vorapaxar would be the third antiplatelet agent), then the meta-analytic HR for hemorrhagic stroke was 1.04 (95% CI, 0.58-1.84; Figure 3D ) with no evidence of heterogeneity (I 2 , 0%).
DiscUssiOn
Stroke remains a frequent cardiovascular complication impacting >10 million people globally each year. 1 It is a major cause of disability and a leading cause of mortality. A significant proportion of strokes occur in the setting of arterial disease such as large vessel atherothrombosis. To that end, antiplatelet therapy with aspirin reduces the risk of recurrent stroke by ≈15%. 12 Although substituting clopidogrel or ticagrelor for aspirin has not been shown to result in statistically significant reductions in stroke, trends toward a reduction in ischemic stroke on the order of 5% to 10% have been observed. 13 
Efficacy of Ticagrelor 60 mg Twice Daily for Any Stroke Up to 3 Years
Any Stroke Up to 3 Years (%) Figure 1 . stroke reduction with ticagrelor 60 mg over 3 years in patients with prior myocardial infarction.
BID indicates twice daily; and HR, hazard ratio.
intensive antiplatelet therapy with >1 agent does reduce the risk of ischemic stroke, but typically at the cost of intracranial bleeding in these patients with prior infarction of brain tissue. [15] [16] [17] [18] [19] [20] Although patients with a prior stroke are at heightened risk, >80% of strokes occur as first strokes. 1 Patients with atrial fibrillation and hypertension are at clearly heightened risk. Other vulnerable populations for stroke include those with symptomatic atherosclerosis characterized by prior MI. Registries estimate that the annual risk of stroke in a post-MI population is ≈1.4% per year. 2 It is estimated that as many as 1 in 10 patients who experience an MI will have a stroke within the next 5 years. 1 Importantly, because of their underlying atherosclerosis, the post-MI population is one which may be particularly likely to experience large vessel atherothrombotic stroke and therefore to potentially benefit from intensive antithrombotic strategy.
In the present patient population, at high risk for stroke but largely without a history of prior stroke, longterm secondary prevention with ticagrelor 60 mg twice daily added to low-dose aspirin reduced all stroke. This benefit for stroke was driven by a reduction in ischemic stroke with, in this selected population, no counterbalancing increase in hemorrhagic stroke or ischemic stroke with hemorrhagic conversion. The reduction in stroke observed with ticagrelor 60 mg twice daily was consistent across the severity scale including a significant reduction in strokes resulting in at least moderate persistent disability or death within 30 days after discharge. The benefit of ticagrelor was consistent across key clinical subgroups. When combined with other data sets evaluating more intensive antiplatelet strategies for long-term secondary prevention, we observed a consistent association between more intensive antiplatelet strategy and a reduction in stroke driven by a 34% reduction in ischemic stroke. When restricting to cohorts that examined aspirin and an additional agent versus aspirin alone, this benefit was not associated with a significant increase in hemorrhagic stroke or hemorrhagic conversion of ischemic stroke. Although these findings support the hypothesis that more intensive antiplatelet strategies are effective for not only MI, but also stroke prevention in appropriately selected populations, they should be considered within the limitations of the meta-analysis presented. In addition, the effect observed should not be extended to other populations. For example, dual antiplatelet therapy did not prove superior to aspirin monotherapy in high-risk asymptomatic patients, including those with asymptomatic carotid disease. 21 Similarly, although dualantiplatelet therapy is superior to aspirin monotherapy in patients with atrial fibrillation, both are inferior to anticoagulation. 22, 23 It is important to distinguish our findings from data in a patient population we did not study, namely patients with prior stroke, in whom data suggest either lack of benefit or an increased risk of intracranial hemorrhage. [15] [16] [17] [18] [19] Differences in efficacy may be explained by the heterogeneous etiologies of stroke (eg, lacunar, cardioembolic, atherothrombotic) and the possibility that not all stroke risk is modified by antiplatelet therapy. For example, cohorts selected for specific types of stroke such as lacunar stroke have been shown clearly not to benefit from long-term dual-antiplatelet therapy. It is possible, however, that long-term dual-antiplatelet therapy does reduce atherothrombotic stroke in the same way it reduces atherothrombotic MI and that prior-MI are most vulnerable to atherothrombotic stroke. And in terms of safety, we deliberately excluded patients with prior stroke because of the increased risk of intracranial hemorrhage with more intensive antiplatelet therapy that has been seen in other trials. [15] [16] [17] [18] [19] [20] These observations should be taken within the context of the overall efficacy and safety of long-term ticagrelor. Overall, ticagrelor reduced the composite of cardiovascular death, myocardial infarction, and stroke at the cost of increased TIMI major bleeding. For 1000 patients initiated on ticagrelor 60 mg twice daily for 3 years, ≈5 ischemic strokes would be prevented with no excess of hemorrhagic stroke. When evaluating the broader efficacy and safety of long-term ticagrelor in this population, for 1000 patients initiated on ticagrelor 60 mg twice daily for 3 years, 13 cardiovascular death, MI, or stroke events would be prevented at a cost of 9 TIMI major bleeds but no fatal bleeds. were selected in that they were required to have at least 1 high-risk feature for ischemic complications (age >65 years, diabetes mellitus, multivessel coronary disease, multiple prior MIs, chronic kidney disease) and were excluded if they were at heightened bleeding risk (eg, re-cent bleeding, need for anticoagulation, prior intracranial bleeding). The findings should not be generalized to other populations, in particular, those at lower ischemic risk or at higher bleeding risk. The pathogenesis of stroke was not ascertained and therefore the events reported Figure 3 . the effect of potent antiplatelet therapy versus placebo for all stroke (a), ischemic stroke (B), hemorrhagic stroke (c), and hemorrhagic stroke limiting to subgroups comparing dual-antiplatelet therapy (aspirin and a P2Y 12 inhibitor or aspirin and a Par-1 inhibitor) to aspirin alone (D).
ORIGINAL RESEARCH ARTICLE 869 may represent several etiologies, including atherosclerotic stroke, cardioembolic stroke, and lacunar stroke. It is also possible that the benefit of ticagrelor for reducing stroke was not homogenous across these etiologies.
Because the population was one of patients with prior MI largely without history of stroke, it is likely that the majority of strokes were atherosclerotic in etiology. To that end, in patients presenting with a stroke, the use of more intensive antiplatelet therapy tended to reduce atherosclerotic ischemic stroke with no benefit for nonthrombotic strokes such as lacunar stroke. 19 Although no significant differences in efficacy were observed in the subgroups evaluated, there were trends for slightly greater magnitude of effect in patients with risk factors for stroke. Future analyses of other large data sets will be needed to examine this issue further. In addition, it should be noted that the meta-analysis included patients with coronary disease, which includes a spectrum of disease, included antiplatelet agents with differing mechanisms of action, and that background therapies were not identical in all trials. Combining the trials as a meta-analysis was intended to show the consistency of ischemic stroke reduction with more intensive antiplatelet strategies in patients with coronary disease and predominantly prior MI.
cOnclUsiOns High-risk patients with prior MI are at long-term risk of stroke, primarily because of ischemic stroke. Outcomes in patients with stroke are poor with >30% resulting in moderate to severe disability or death. The addition of a second antiplatelet agent to aspirin as long-term secondary prevention in patients with coronary disease reduces the risk of stroke by ≈34% without a counterbalancing risk of hemorrhagic stroke or hemorrhagic conversion after ischemic stroke but with more major bleeding. Stroke prevention should be considered when weighing the risks and benefits of long-term antiplatelet therapy in high-risk patients with coronary disease.
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